Bayer (BAYN) PT Set at €85.00 by Barclays

Barclays set a €85.00 ($98.84) target price on Bayer (FRA:BAYN) in a research report report published on Tuesday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the healthcare company’s stock.

Several other equities analysts also recently weighed in on the company. DZ Bank reissued a neutral rating on shares of Bayer in a research report on Tuesday. Goldman Sachs Group set a €77.00 ($89.53) target price on Bayer and gave the company a buy rating in a research report on Tuesday. Baader Bank set a €123.00 ($143.02) target price on Bayer and gave the company a buy rating in a research report on Tuesday. Sanford C. Bernstein set a €89.00 ($103.49) target price on Bayer and gave the company a buy rating in a research report on Tuesday. Finally, JPMorgan Chase & Co. set a €70.00 ($81.40) target price on Bayer and gave the company a neutral rating in a research report on Tuesday. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and twelve have assigned a buy rating to the stock. Bayer presently has an average rating of Hold and a consensus target price of €81.67 ($94.97).

FRA BAYN opened at €55.51 ($64.55) on Tuesday. Bayer has a fifty-two week low of €91.58 ($106.49) and a fifty-two week high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

See Also: Stock Ratings and Recommendations: Understanding Analyst Upgrades and Downgrades

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.